Tocilizumab [375823-41-9]

Cat# HY-P9917-1mg

Size : 1mg

Brand : MedChemExpress

Contact local distributor :


Phone : +1 850 650 7790

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).

For research use only. We do not sell to patients.

Tocilizumab Chemical Structure

CAS No. : 375823-41-9

*

This product is a controlled substance and not for sale in your territory.

  • J Biomed Sci. 2022 Nov 24;29(1):101.  [Abstract]
  • Cell Death Dis. 2021 Dec 20;13(1):16.  [Abstract]
  • Breast Cancer Res. 2023 Apr 17;25(1):43.  [Abstract]
  • Immunology. 2023 Apr 17.
  • Phytomedicine. 2023 Jan 11;111:154659.  [Abstract]
  • Cell Biol Toxicol. 2021 Oct 25.  [Abstract]
  • Sci Rep. 2023 Aug 14;13(1):13231.  [Abstract]
  • Biochem Pharmacol. 2023 May 19;213:115618.  [Abstract]
  • Carcinogenesis. 2023 Mar 20;bgad013.  [Abstract]
  • Sci Rep. 2022 Jan 20;12(1):1075.  [Abstract]
  • Endocr Relat Cancer. 2023 Jun 1;ERC-23-0130.  [Abstract]
  • Oral Dis. 2023 May 30.  [Abstract]
  • Int J Chron Obstruct Pulmon Dis. 2023 Apr 13.
  • Biochem Bioph Res Co. 2023 Feb 19.
  • Toxicol Appl Pharmacol. 2022 Feb 11;115921.  [Abstract]
  • SSRN. 2024 Feb 7.
  • Research Square Print. October 3rd, 2022.
  • Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep.
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).

IL-6

 

In Vitro

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab.
? Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml.
? Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells.
? Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line: Human-derived HARA-B cells
Concentration: 1 ng/mL, 10 ng/mL, and 100 ng/mL
Incubation Time: 24 hours, 48 hours
Result: Inhibited the IL-6R expressed on human-derived HARA-B cells.

Cell Cytotoxicity Assay

Cell Line: Ba/F3-gp130-IL-6R cells
Concentration: 0.001–10000 μg/ml
Incubation Time: 2 days
Result: Inhibited Ba/F3-gp130-IL-6R cell proliferation.

Western Blot Analysis

Cell Line: SAS cells
Concentration: 1 μM
Incubation Time: 6 hours
Result: Reduced the phosphorylation of STAT3.

RT-PCR

Cell Line: SAS cells
Concentration: 1-5 μM
Incubation Time: 24 hours
Result: Reduced VEGF mRNA expression.
In Vivo

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains.
? Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice

Liquid

Colorless to light yellow

[Tocilizumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

  • [1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.  [Content Brief]

    [2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526.  [Content Brief]

    [3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.  [Content Brief]

    [4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954.  [Content Brief]

  • [1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.

    [2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526.

    [3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.

    [4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Immunology/Inflammation
  • Interleukin Related

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
HY-100461-1mg
 1mg 
A10970-1
 100ug/vial